
Curriculum Vitae (redatto in forma di autocertificazione, ai sensi degli artt. 46 e 47 del DPR n. 445 del 28 dicembre 2000):

Il sottoscritto Giovanni Cazzaniga

DICHIARA

che le informazioni riportate nel curriculum che segue corrispondono a verità.
In fede

Giovanni Cazzaniga



CURRICULUM VITAE

Name	Giovanni Cazzaniga
Date and place of birth	24 September 1965, Vimercate (MI), Italy
Citizenship	Italian

ORCID ID: 0000-0003-2955-4528
SCOPUS AUTHOR-ID: 7004048814
RESEARCH ID: AFG-4357-2022

Work addresses

Tettamanti Center, Pediatrics
Fond. IRCCS San Gerardo dei Tintori
Centro Maria Letizia Verga, Via Cadore snc
20900 Monza (Mi), Italy
Phone:+ 39 039 2333661
giovanni.cazzaniga@unimib.it

Medical Genetics
Fondazione IRCCS San Gerardo dei Tintori
Via Pergolesi 33
20900 Monza (Mi), Italy
Phone:+ 39 039 2333461 / 4541
giovanni.cazzaniga@irccs-sangerardo.it

EDUCATION

2021	Associate Professor, Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.
2018	Assistant Professor (Ricercatore a Tempo Determinato di tipo B, RTDB), Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.
2014	Qualification (National Scientific Habilitation, ASN) for Associate Professorship to the following sections: 05/F1 Applied Biology BIO/13 and 06/A1 Medical Genetics MED/03, 06/A2 General and Clinical Pathology (deadline 07/01/2023).
2004	Specialist in Medical Genetics. Faculty of Medicine, University of Milan, Italy. *70/70 cum laude.*
1992	Specialist in Pharmaceutical Research at the "M.Negri" Pharmacology Research Institute of Milan, Italy.
1990	Biological Science degree at the University of Milan, Italy. *110/110 cum laude.*

PROFESSIONAL POSITION

05/2023 - now	Acting Director (ff), Medical Genetics, Foundation IRCCS San Gerardo dei Tintori, Monza, Italy
03/2023 - now	Deputy Director, Ph.D. Program in Translational and Molecular Medicine (Dimet), University of Milan Bicocca.
12/2021 - now	Associate Professor, Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.
2006 - now	Head, "Molecular genetics of leukemia" Unit, Centro Ricerca Tettamanti, Pediatric Clinic, University of Milan-Bicocca, Monza, Italy.
2018-2021	Assistant Professor (Ricercatore a Tempo Determinato di tipo B, RTDB), Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.
2009 - 04/2023	Director, Laboratory of Hemato-Oncology Diagnostics "M. Tettamanti", Fondazione MBBM, Monza.
1995/1997	Research fellow at the "M.Tettamanti" Research Center, Pediatric Clinic, University of Milan-Bicocca, Ospedale San Gerardo, Monza, Italy.
1990/1994	Research fellow at the Laboratory of Enzymology - Molecular Biology Unit - "M.Negri" Pharmacology Research Institute, Milan, Italy.

MAJOR RESEARCH INTERESTS

- Genetic predisposition to leukemia
- Personalized Medicine in Pediatric Hemato-Oncology
- Prenatal origin of leukemia
- Heredo-Familial Cancers
- Molecular characterization of childhood ALL and AML.
- Minimal residual disease monitoring in childhood ALL, by analysis of T-cell Receptor and Immunoglobulin genes' rearrangements and fusion gene transcripts.
- Functional analysis of genetic aberrations in leukemic patients (PAX5 lesions, Ph-like ALL, Down Syndrome ALL, MLL-rearrangements).

ORGANIZATIONAL / EDUCATIONAL / MANAGERIAL SKILLS

- Since 2023: Head of the Medical Genetics Unit at the Fondazione IRCCS San Gerardo dei Tintori, Monza (IT), coordinating a team of 2 clinical geneticists, 4 cytogeneticists, 3 molecular biologists, and 6 technicians focused on prenatal and postnatal analyses on genetic disorders, hemato-oncological cytogenetics, clinical genetics focused on cancer predisposition.
- Since 2006: Group Leader of the 'Molecular Genetics of Leukemia' Unit at the Tettamanti Research Center, coordinating a team of 3 PostDocs, 2 Physician Scientists, 6 PhD students and 2 rotating ungraduated students.
- Since 2022: Chair of the Committee on Genetic Variations of the International-BFM Study Group (a Working Group of the European Society for Paediatric Oncology- SIOP Europe, which networks national study groups from more than 30 Countries worldwide, to address research on pediatric leukemia and lymphoma)
- Since 2023: Designed Member of the "Regional Committee for the Laboratory Medicine Services (CReSMeL)", Lombardy Region, Italy.
- Since 2022: Substitute Delegate of University of Milano Bicocca to The European Paediatric Translational Research Infrastructure (EPTRI), an EU-supported initiative (EU-EPTRI-ID n. 777554)

- 2022: Contributor to 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours (4th Chapter: B-cell lymphoid proliferations and lymphomas - sessions on BCR::ABL1 fusion, ETV6::RUNX1 fusion, ETV6::RUNX1-like features, TCF3::PBX1 fusion, TCF3::HLF fusion). Leukemia. 2022 Jun 22. doi: 10.1038/s41375-022-01613-1.
- 2009-2022: Head of the Laboratory Tettamanti for Hemato-Oncological Diagnostics, coordinating 15 biologists and technicians working on cytomorphology and immunophenotyping, cytogenetics/molecular cytogenetics and molecular biology, for the diagnosis and monitoring of childhood and adult leukemia. The Laboratory if National reference for childhood ALL, and one of the main regional references for CML/MPD.
- Founder and Board Member of the European Group for Minimal Residual Disease (EuroMRD, www.euromrd.org) analysis; Steering Committee member of the Euroclonality-NGS group, member of the Biology & Diagnosis Committee of the International-BFM Study Group (I-BFM-SG); board member of the Working Group on Biology of the Italian Association for Pediatric Hemato-Oncology (AIEOP); Management Committee member of the COST Action 'Legend' and vice-chair of WG3 on 'Familial Leukemia'; Committee of the International PhD in Molecular and Translational Medicine (DIMET-Università Milano Bicocca, Monza).
- Large experience in training and supervising students. Overall, 6 PhD students for the International PhD in Molecular and Translational Medicine (DIMET-Università Milano Bicocca, Monza); 3 PhD students for the International PhD in Molecular Medicine (Università Vita-Salute San Raffaele, Milano); 3 students for their post-Degree Specialization in Medicine (Università Milano Bicocca, Monza); 13 students for their degree in Medicine (Università Milano Bicocca, Monza); 12 students for their degree in Biotechnology or Biology (Università Milano Bicocca, Monza and Università degli Studi, Milano); 4 students for their degree as Laboratory Technician (Università Milano Bicocca, Monza).
- Since 2011: yearly Teacher at the Master on Pediatric Hematology, Sapienza University, Rome, IT
- Since 2019: teaching Genetics in courses for Medical Doctors, Biotechnologists and Technicians at the University of Milan Bicocca.

HONOURS AND AWARDS (personal and of the group)

- 2015 Cazzaniga V/Cazzaniga G. Best Thesis: PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5. 29th National Conference of Cytometry (GIC), Salerno, Italy. Lettere GIC 2011;20:27-30
- 2014 Bardini M/Cazzaniga G. 'Mundipharma Hematology Award'. National Contest, SIES 2014: Scientific paper: Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia 2015.
- 2014 Palmi C/Cazzaniga G. 'Under 40- Young in Hematology', National Contest, SIES 2014: Research Project: 'CRLF2 Over-expression is a Poor Prognostic Marker in Children With High Risk T-cell ALL'.
- 2006 Palmi C/Cazzaniga G. Best Poster at the 5th Bi-annual Symposium on Childhood Leukemia; 'Expression of the TEL-AML1 leukemia-associated fusion protein inhibits TGF-beta1 signaling'.
- 2006 Palmi C/Cazzaniga G. Poster "Scholar in Training awardee" at the AACR Special Conference in cancer Research, California (USA).

- 1998 Cazzaniga G. Best abstract at the AIEOP Congress (Pavia). 'Prenatal origin of leukemia'.
- Several ASH, EHA, SIES travel awards to the personnel of the group through the years.
- Several peer reviewed fellows and University positions to the personnel of the group through the years.
- Advisory Board of the project "Responsible Initiative on Neonatal Genome Sequencing" (RINGS), cofunded by Lombardy Region and Telethon Foundation, to assess the feasibility on Neonatal WGS.

PEER REVIEWED GRANTS

As 'PI':

Ongoing:
- Italian Association for Cancer Research (AIRC) – IG 2023 ID 29175 (2024-2028): Before leukemia in children: PRE-disposition, PRE-leukemia for PRE-vention (PRE3vent)' (Euro 1.026.000).
- PRIN: Progetti di Ricerca di Interesse nazionale – Bando 2022, Prot. 2022WMAT29 (2024-2025): 'Precision drug targeting of high risk relapsing childhood acute lymphoblastic leukemia' Role of Coordinator (Euro 122.702 for the Unit; total Euro 318.950).

Completed:
- Italian Association for Cancer Research (AIRC) – 2019-2023 - Childhood Acute Lymphoblastic Leukemia: a path back, from genetic predisposition through pre-leukemia (Euro 687.000).
- TRANSCAN-2 JTC 2017_Quant-ALL-0622: 'Automated, absolute quantification of MRD in ALL patients by droplet microfluidics, single DNA copy barcoding and IG/TR amplicon NGS'. PI Unit: G.Cazzaniga (Euro 250.000).
- H2020-MSCA-ITN-2018- Proposal number: 813091: ARCH: Age-Related Changes in Hematopoiesis. PI: Antonella Ronchi (Unimib, Milano, IT); PI Unit: G.Cazzaniga (Euro 252.500)
- Italian Association for Cancer Research (AIRC) – 2016-2018 - A comprehensive sequencing platform for precision medicine in childhood acute lymphoblastic leukemia
- Italian Association for Cancer Research (AIRC) – 2013-2015 -Next Generation Sequencing to improve diagnostics and molecular dissection of childhood leukemia
- Fondazione Cariplo - 2011-2013 - Identification and functional characterization of new risk factors in childhood acute lymphoblastic leukemia.
- Italian Association for Cancer Research (AIRC) – 2010-2012 - High throughput sequencing for dissecting the complexity of childhood ALL.
- Italian Association for Cancer Research (AIRC) – 2007-2009 - Identification of new genomic lesions in childhood ALL with "normal karyotype" by a comprehensive approach.

As 'Head of Unit':

Completed:
- Fight Kids Cancer - Project Number: 22-FKC-21. Project Title: Finding a cure for MLL-rearranged infant acute lymphoblastic leukaemia (Cure2MLL). 2022-23. PI Unit: G.Cazzaniga (Euro 60.000).
- COST Action OC-2016-2-21584 (Call OC-2016-2). PI: Esme Wanders (Utrecht, NL) Leukemia GENe Discovery by data sharing, mining and collaboration (LEGEND). Italian Member: G.Cazzaniga

As 'Collaborator':

Ongoing:

- PNRR Progetto 'HEAL Italia' 2022-NAZ-0458, SPOKE 5: Next Gen Therapeutics, WP 4: Identification of new therapeutic targets by screening and drug repositioning. Univ. Milano Bicocca, Dip. Medicina e Chirurgia (Euro 143.865,42)

Completed:

- Transcan - European Union, FP7 - PI Unit:Andrea Biondi: Validation of the impact of genetic aberrations and host genetic variation in childhood acute lymphoblastic leukemia for integration into clinical practice (Euro 261.884)
- Marie Curie Initial Training Networks (ITN) - Call: FP7-PEOPLE-2011-ITNEuropean Union, FP7 – PI: Antonella Ronchi (Unimib, IT); PI Unit: Andrea Biondi: Hem_Id - HEMatopoietic cell Identity, genetic and epigenetic regulation in normal and malignant hematopoiesis.
- FP7-HEALTH-F2-2011 Contract no. 261474 - European Union, FP7 - PI Andrea Biondi: ENCCA - European Network for Cancer Research in Children and Adolescents.
- Italian Association for Cancer Research, Fondazione Cariplo, Italian Ministry of University and Research - PI Andrea Biondi: several peer reviewed grants in the last 15 years.

SOCIETIES

- Member of the Italian Society of Human Genetics (SIGU)
- Member of the Italian Association of Familial and Hereditary Tumors (AIFET)
- Member of the American Society of Hematology (ASH)
- Member of the European Society of Hematology (EHA)
- Member of the Italian Association of Pediatric Hemato-Oncology (AIEOP)
- Member of the Italian Society of Experimental Hematology (SIES)
- Board Member of the European Study Group for Minimal Residual Disease in Acute Lymphoblastic Leukemia (ESG-MRD ALL)
- Member of the Steering Committee of the Euroclonality-NGS Group.

COLLABORATIVE PROGRAMS

2018-now	JakNet - Italian network on Ph negative Myeloproliferative Disorders.
2018-now	LabNet AML- Italian network on Acute Myeloid Leukemia.
2016-now	Campus ALL – Italian network on diagnosis, prognosis and treatment of ALL.
2015-now	I-BFM Genetic Variation Task Force. Network on genetic predisposition to leukemia.
2013-now	LabNet CML - Italian network on Cronic Myeloid Leukemia
2013-now	EuroClonality-NGS Consortium on Next-Generation Sequencing for IG/TR immunogenetic analysis.
2008-now	European Study Group on MRD detection in ALL (ESG-MRD-ALL). Standardization and Quality Control of RQ-PCR for BCR/ABL1 and ABL1 mutations.
2002-now	European Study Group on MRD detection in ALL (ESG-MRD-ALL). Standardization and Quality Control of Clonality analysis and RQ-PCR for IG/TR.
2000-now	MRD-Task Force: Report, Quality Control and Research Projects within the running childhood ALL therapeutic protocol in Italy, Germany, Austria (AIEOP-BFM ALL2000).
1999-now	International-BFM Study Group. Biology and Diagnosis Committee.

2016-2021 COST Action OC-2016-2-21584 (Call OC-2016-2). PI: Esme Wanders (Utrecht, NL) Leukemia GENe Discovery by data sharing, mining and collaboration (LEGEND). Italian Member.

1999-2002 Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program.

1995-1998 BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.

- "Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease".
- "Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets".

EDITORIAL ACTIVITIES

Journal Board

- Associate Editor of the session on Pediatric Hematology and Hematological Malignancies, within Frontiers in Pediatrics.

Referee

- Reviewer of Nature Genetics, New England Journal of Medicine, Blood, Leukemia, Haematologica-The Hematology Journal, Leukemia Research, Leukemia and Lymphoma, Advances in Hematol, Ped Hematol Oncol, Ped Reports, Ped Blood and Cancer, and others.
- Reviewer of International Grant programs, member of the Scientific Committee of the Italian Association for Cancer Research (AIRC) for evaluation of Investigator Grants.
- Abstracts Reviewer for the American Society of Hematology, European Hematology Association and ESLHO meetings.

PUBLICATIONS / INDEXES

- Number of total publications in peer-review journals: *284 (including 11 reviews and 3 book chapters)*
- H-Index: 76 (Google Scholar, 13/11/2024)
  - Total number of citations: 26583 (Google Scholar, 13/11/2024)
  - The ASN 2023-2025 simulation gave positive results for the roles of 'Full Professor and Committee member'.

I herewith authorize to process my personal data in accordance to Italian D.Lgs. 2018/101 and GDPR (Regulation EU 2016/679).

Monza, 13/11/2024

Giovanni Cazzaniga

